{"name":"Zealand Pharma","slug":"zealand-pharma","ticker":"ZEAL","exchange":"NASDAQ / OMX Copenhagen","domain":"zealandpharma.com","description":"Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley.","hq":"Copenhagen, Denmark","founded":0,"employees":"","ceo":"","sector":"Obesity / Metabolic / Peptide Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":450000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2021-01-01","label":"Zegalogue first approved","drug":"Zegalogue","drugSlug":"dasiglucagon","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dapiglutide 7.5 mg","genericName":"Dapiglutide 7.5 mg","slug":"dapiglutide-7-5-mg","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Zegalogue","genericName":"DASIGLUCAGON","slug":"dasiglucagon","indication":"Hypoglycemia due to diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Dapiglutide 7.5 mg","genericName":"Dapiglutide 7.5 mg","slug":"dapiglutide-7-5-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zegalogue","genericName":"DASIGLUCAGON","slug":"dasiglucagon","phase":"marketed","mechanism":"Zegalogue works by stimulating the release of glucose from stored energy sources in the body.","indications":["Hypoglycemia due to diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxONXVESi11QjIxZ2FWaTh2MkN2bGpMdGxodUFkWkhyUE1DX013VjBiQnd6U01SSXdxZkF5cW9XLTc3QzlJQWNSWUpRRjNpcUk5N3ozS0ZMUGNZb3FhWjZTeVRKYjVQQ2NjaW1sMndMVVdMN3pINzlOQ0Nndk1NRVVPMlhwbnpxZmIzZ21LTDdnUGZSX3dZaGVEeEdpN2JwdVdGY1B3TFRkcS0zYUEtUVE2Tmo4Mk1XRk1YaEZaaVhrMUdhY05VeUIwVXpMaw?oc=5","date":"2026-04-08","type":"trial","source":"TipRanks","summary":"Zealand Pharma Advances Obesity Pipeline With Completed Petrelintide Dose Study - TipRanks","headline":"Zealand Pharma Advances Obesity Pipeline With Completed Petrelintide Dose Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQa0d6bFpLMGlvZFcxZExfM1F4TTNNQ0xaRlBjTzJGQ0NKOG4zSlk4bkpfVVBoQ0tjcmd5QjJSNG41c0VuWUJXQTZTdHFNVHJ6d0c4b0VoVjJMcWpmY3dUVEtPSzBxTmxtTzlxQS1IdnhiQy1fc0lCN1Jla0ZJXzZEOG9CZ0F4Q1QyQ3dkNWhsazkwUXhtLVlHSU50VzB2bHNNMlFqemFKZHczY2c1Mkl1OFQ3RUR4SzQ?oc=5","date":"2026-04-07","type":"pipeline","source":"MarketBeat","summary":"Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Should You Sell? - MarketBeat","headline":"Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Should You Sell?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After New AI-Focused Cambridge Research Hub Announcement - simplywall.st","headline":"Assessing Zealand Pharma (CPSE:ZEAL) Valuation After New AI-Focused Cambridge Research Hub Announcement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9DaTVidkN6YV9OMVZNUFh6a0lBZDhLN0c1UWhTX3YxMUcxRGlkRlpHaDBNN1l5N0VsMGR3cnZQZnUyVnBwYUtSVXVybFBadGVOMXZ1N2NXdngzT3VF?oc=5","date":"2026-04-04","type":"pipeline","source":"GuruFocus","summary":"Zealand Pharma AS (WBO:ZEAL) Stock News, Headlines & Updates - GuruFocus","headline":"Zealand Pharma AS (WBO:ZEAL) Stock News, Headlines & Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPR29hM1VaQzYxdWRSaWZmV3o1NElKUEZhcDBBLTEyaUg2Q212YVBaVU1KdzZQcDliNHdJdXB5NUNMWk9WZDVjZUVWYnZ6SVlMZE9mWU1CUmlFdXROSmhEaTdTZnY3UTZJR2d2cUZtZ1NtckpPTzIzTDJTUUpqLVBqQnE0dTUtUlZlYlI4WTNsZy05Z0k?oc=5","date":"2026-04-03","type":"earnings","source":"Yahoo Finance","summary":"Zealand Pharma A/S N (22Z.DU) Q2 FY2025 earnings call transcript - Yahoo Finance","headline":"Zealand Pharma A/S N (22Z.DU) Q2 FY2025 earnings call transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOUGNDQ2MwcnItUGt1Q3c2eWlGZ1ZFM0JidjhOWmhZX1ItU1U2LU1RTWg2UGVfd0dVR2h2X3FIOTFUSkFrbGh6TEs3VHpSMmhpeHlZNElSNmoxN1lKbGJycUExTG9OT2lVckhJLS12MGhSanVQRWxzVnhXYlR3NkhUdVlKdVppQlR2Ylg5cVlpb3ViQmdqaXJQVkhmbXlETG1GNmxibTVvTkdfek96RnB1TFVZeVpUU2NSdGxHRVlLNVR2SXNwMnpJ?oc=5","date":"2026-03-26","type":"pipeline","source":"Investing.com","summary":"Wolfe Research initiates Zealand Pharma stock with outperform rating - Investing.com","headline":"Wolfe Research initiates Zealand Pharma stock with outperform rating","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxNR3BRZHRLNjVoaDlxQnA1R0dGcXdsdDMzRXlOYS0zV0Z6MWlILTVqNjFuLWt4aXlaZTNySEZwM2FTM3VJeHFWYy1UWkJia29GS1pFcDRKTEwtam50QnpicEJLUTBNTktMUjlGOGNBREt6S19rOHVBdnBGd3gycFZlNWxtVHF3dG1tcC1HQk10QzZWNC1xVG14WjlCR3FxYUVPamVRX2YwbEFib1YzRWhYZTA1VHEwbEU2MjZ6NU42OU5DUUp2VkhRTW0tSXNtQS1kSnV6M0lncXB0QTF1bE1UdjZqRk5ncmhmd0Ezc1o1VmV5SF9ld2FSc0dPX1c4YUMtNEhzUUdVMjF6M3dMdFQtYll6T2JEODVuRTVRNnFIQXE5T3c2Y1J4TGd4eFg4dHRlYXdQX1Fxc1k?oc=5","date":"2026-03-24","type":"pipeline","source":"GlobeNewswire","summary":"Zealand Pharma Establishes U.S. Research Hub in Cambridge, - GlobeNewswire","headline":"Zealand Pharma Establishes U.S. Research Hub in Cambridge,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOQURLb2hfVlV2MHZZT21TeE1ZM0h0bzY4T1hfYkM0S1lOZUhMSDBIZFgycXJNQzB2TC1XMWJORW9MY1d3U3MwRzFfSS04dWN2SjRtcjJIcDhaVV8tNEdoTTlYY1FNS1ozbEt6VDdiSmYwNjdXQWJDQUVjV1FzS1Y0U2FVVHhzQTd2Vlo0Q1JYTVJaWFJLUzRiV2QxbWRTWFk1aENpOXlNOGpESmxvN2FmaS1jbw?oc=5","date":"2026-03-20","type":"pipeline","source":"CoStar","summary":"News | Weight loss drugmaker Zealand Pharma selects Boston to anchor US growth - CoStar","headline":"News | Weight loss drugmaker Zealand Pharma selects Boston to anchor US growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOczFLcXNibjJYa2wtMEhOQWlveUpoOS1qR0YxcDh2bmdpV240TEdGa29mMzJyRTdNWlp1NF9iWW1xcmJFdU52NmEzcEptSzk1YVhaZHY3M3hxSHNncnUyQm05LUV6Z1N5VHpsUFh2NGZJeldsQ1VQU0dPMWFmWFlzckJUX3liRFVEYVlTMUcwX250cEh4WUVvLWRkSEY4WFVaMGNEMlF6Yw?oc=5","date":"2026-03-06","type":"pipeline","source":"WSJ","summary":"Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market - WSJ","headline":"Zealand Pharma CEO Says Most-Tolerable Drugs Will Be Next to Win in Obesity Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQRm5aNW0xOGU4NjdzVmNCRElzMFYyM0tmb29WS2NqTXdXVFVSb3pjMHJGbVRyZmN5VjlWd2l2Ym1EelNLei1DdENWc2YyaTVsMlpxQUZsUFVxX0tLY0tmcGFJcTNZQ0Y3NkR5LWF5MkhCZ1hYOW54ODdWY2hNQUFzd2MxcjFLVl9uNWdmMk12SnR0Vnd1N0puRmJ5Ml82ZHkyRU14QllOTGpsXzEzcGZ2aEpOdmpReHJOQWxsYVZFSUE3QQ?oc=5","date":"2026-03-06","type":"pipeline","source":"MarketWatch","summary":"This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling - MarketWatch","headline":"This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOWlB3NlUwQUhicnc3THNNNXAxaEpkODdCRG5DRm5qWE1kVmZJeDFtS3FKNVlGS3IzQXNUcjE3RHBKdUtJZk1QSVFlX21vR3lDWEZKaUx6RWUtQmJ0N1JzMDM2QXluTmFmOTJ3UWFOS2swdlJOQlo3U2hXSUYyaEdYeE5XNl9vSXozNW5Cd3hpY2xpTHpieVdXMU50a2tndmRuTVRhRVdfc1TSAa4BQVVfeXFMTTA1dVFWVldhX0NGYmtKN2cxQWJiRHkwZkh3VFRrTUJGUXJCN3lla2U0YzlZSzM3bmFEMjl2bTVhZ0RtVHhUTzBHOWhnR3h5bU9rV0F1ZzN5RllmRVNMRzJNWGNzUk5yQkhZTkhZV1ptSVhzdnJyaWZGT3JoRDJ5RDRwOG4zT0g2bnUwcW1LQTVyYkpIcV9pZXU2a2dJQ3dLUFdOTlg0OVphanNKZi1B?oc=5","date":"2025-12-11","type":"pipeline","source":"CNBC","summary":"Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly - CNBC","headline":"Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOSlpkR0cwcEFDMHNZek00Q0U1RGRLVHJCY3pBZWZqVkVFbzQwa3Z0bG9jYzNFOXJKaUY4bVlpdjZseGNLZlhTSkdvMm1PaXVRN29aZF9ZV3RFS3VNLWkyQlRlUFBENk5FYnlQOXhfenFWYlNaUEJiVTdPYXVmNlVsV3daWDVKdllWUzFwcExCdkNMaVAtUHdMWDZGcUgybDhGSnVrMzRUdlRMUzNRZk9iYk95QkRRakpiQ3FIVTI1TUd6SlM2RVEybmZBS0d4RDZHVzg1d1BuSXp1SmJ0?oc=5","date":"2025-12-11","type":"pipeline","source":"Reuters","summary":"Zealand Pharma seeks to challenge GLP‑1 dominance with obesity drug aimed at long‑term use - Reuters","headline":"Zealand Pharma seeks to challenge GLP‑1 dominance with obesity drug aimed at long‑term use","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}